ALK(SZ:002940) Xin Lang Cai Jing·2025-10-24 02:33Core Viewpoint - The stock of Anglikang has experienced significant fluctuations, with a year-to-date increase of 202.50% but a recent decline of 11.87% over the past five trading days, indicating volatility in investor sentiment and market performance [1]. Company Overview - Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and went public on October 23, 2018. The company is located in Shengzhou, Zhejiang Province, and specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition of Anglikang includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), other products (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported an operating income of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% compared to the previous year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders of Anglikang increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, Guangfa Technology Innovation Mixed A, and others, indicating increased institutional interest in the company [3].